Page 14 - Peter Stein News Today

" Er drängte sich nie vor, aber machte dann aus jeder Nebenrolle eine Hauptfigur", sagt Theaterregisseur Claus Peymann über Otto Sander, den er 1968 ins Ensemble der Freien Volksbühne Berlin holt. Da hat Sander bereits erste Engagements in Düsseldorf und Heidelberg sowie an Privat- und Kleinkunstbühnen in München. In den folgenden Jahren wird er zu einem der gefragtesten Darsteller Deutschlands. Sanders Entscheidung für die Schauspielerei ist allerdings eine Art Flucht nach vorne. Schau...

As the acclaimed actor publishes his memoirs, he recalls his experiences in Romania – with Hamlet and a hard-boiled egg

FDA releases fresh details on internal debate over controversial Alzheimer’s drug Laurie McGinley © Jessica Rinaldi/Pool/Via Reuters Marc Archambault, who has early-stage Alzheimers disease, receives his first dose Wednesday of the newly approved intravenous drug Aduhelm at Butler Hospital in Providence, R.I. (Jessica Rinaldi/Pool/Reuters) The Food and Drug Administration on Tuesday released fresh details on why it approved a controversial Alzheimer’s drug in hopes of q...

米医薬品大手・バイオジェンがエーザイと共同開発したアルツハイマー病治療薬「アデュヘルム（一般名・アデュカヌマブ）」は、米食品医薬品局（ＦＤＡ）が約２０年ぶりに承認したアルツハイマー病向け新薬となった。

By Deena Beasley and Julie Steenhuysen (Reuters) - In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administrati...

In a powerful statement of disagreement with the Food and Drug Administration’s approval of Biogen’s controversial Alzheimer’s drug, three scientists have resigned from the independent committee that advised the agency on the treatment. “This might be the worst approval decision that the F.D.A. has made that I can remember,” said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, who...

The drug was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the disease.

By Deena Beasley and Julie Steenhuysen (Reuters) - In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administrati...

By Deena Beasley and Julie Steenhuysen (Reuters) - In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administrati...

By Deena Beasley and Julie Steenhuysen (Reuters) - In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administrati...